Cytokinetics (CYTK) Misses Q1 EPS by 7c

Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.86 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Largo restructures $82.2M in debt, extending maturity to 2030
• ScanSource (SCSC) Tops Q4 EPS by 32c